R&D | May 23, 2026
WACKER launches contract research services to accelerate next-gen RNA & DNA therapies
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Transition to a fermentation-based globally integrated CDMO platform
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza
BMS is moving beyond conversational AI into what it describes as “agentic” systems
The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
Subscribe To Our Newsletter & Stay Updated
